- Home
- NRIX vs XMTR Comparison
NRIX vs XMTR Comparison
Compare NRIX & XMTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- XMTR
- Stock Information
- Founded
- NRIX 2009
- XMTR 2013
- Country
- NRIX United States
- XMTR United States
- Employees
- NRIX N/A
- XMTR N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- XMTR Industrial Machinery/Components
- Sector
- NRIX Health Care
- XMTR Technology
- Exchange
- NRIX Nasdaq
- XMTR Nasdaq
- Market Cap
- NRIX 1.1B
- XMTR 1.1B
- IPO Year
- NRIX 2020
- XMTR 2021
- Fundamental
- Price
- NRIX $9.50
- XMTR $30.50
- Analyst Decision
- NRIX Strong Buy
- XMTR Buy
- Analyst Count
- NRIX 17
- XMTR 11
- Target Price
- NRIX $30.71
- XMTR $34.09
- AVG Volume (30 Days)
- NRIX 942.9K
- XMTR 619.4K
- Earning Date
- NRIX 04-08-2025
- XMTR 05-06-2025
- Dividend Yield
- NRIX N/A
- XMTR N/A
- EPS Growth
- NRIX N/A
- XMTR N/A
- EPS
- NRIX N/A
- XMTR N/A
- Revenue
- NRIX $56,417,000.00
- XMTR $573,810,000.00
- Revenue This Year
- NRIX $15.73
- XMTR $20.67
- Revenue Next Year
- NRIX N/A
- XMTR $17.40
- P/E Ratio
- NRIX N/A
- XMTR N/A
- Revenue Growth
- NRIX N/A
- XMTR 19.35
- 52 Week Low
- NRIX $8.18
- XMTR $11.08
- 52 Week High
- NRIX $29.56
- XMTR $45.33
- Technical
- Relative Strength Index (RSI)
- NRIX 35.33
- XMTR 68.65
- Support Level
- NRIX $9.02
- XMTR $24.65
- Resistance Level
- NRIX $11.56
- XMTR $31.63
- Average True Range (ATR)
- NRIX 0.61
- XMTR 1.54
- MACD
- NRIX -0.07
- XMTR 0.80
- Stochastic Oscillator
- NRIX 14.29
- XMTR 87.49
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.